<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318939</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-POZ-202</org_study_id>
    <nct_id>NCT03318939</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation</brief_title>
  <official_title>A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the
      safety/tolerability of poziotinib in up to 174 patients with NSCLC exon 20 insertion
      mutations (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon
      20 insertion mutations).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Screening period (Day -30 to Day -1) lasts up to approximately 30 days prior to Cycle 1,
      Day 1. Patients must meet all Inclusion/Exclusion Criteria to participate in the study.
      Eligible patients will provide written Informed Consent prior to undergoing any study
      procedures.

      Each treatment cycle is 28 calendar days in duration. There will be two cohorts and eligible
      patients will be enrolled into each cohort based on EGFR or HER2 exon 20 mutant status:

        -  Cohort 1: Patients with EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)

        -  Cohort 2: Patients with HER2 exon 20 insertion-mutant non-small cell lung cancer (NSCLC)

      Toxicity will be assessed based on the grade of the adverse events using CTCAE version 4.03.

      All treatments will be taken orally, once daily (QD) at approximately the same time each
      morning. On Day 1 of each 28-day cycle, the patient's absolute neutrophil count (ANC) must be
      ≥1.5×10^9/L and platelet count must be ≥100×10^9/L before administering poziotinib. All
      patients will be treated until disease progression, death, intolerable adverse events, or up
      to a maximum of 24 months, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each treatment cycle is 28 calendar days in duration. There will be two cohorts and eligible patients will be enrolled into each cohort based on EGFR or HER2 exon 20 mutant status:
Cohort 1: Patients with EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
Cohort 2: Patients with HER2 exon 20 insertion-mutant non-small cell lung cancer (NSCLC)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of subjects who achieve Complete Response (CR) and Partial Response (PR) by the best response from the first dose of poziotinib to the end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of subjects who achieve CR, PR, and Stable Disease (SD) by the best response from the first dose of poziotinib to the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of days from the date that measurement criteria are first met for CR or PR (whichever status is recorded first) until the first subsequent date that progressive disease or death is documented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-free Survival (PFS) - Exploratory</measure>
    <time_frame>24 months</time_frame>
    <description>Number of days from the treatment start date to the date of documented disease progression or death due to any cause.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Poziotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Patients with EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
Cohort 2: Patients with HER2 exon 20 insertion-mutant non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poziotinib</intervention_name>
    <description>The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.</description>
    <arm_group_label>Poziotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, or patient's authorized representative, must be willing and capable of giving
             written Informed Consent and must be able to adhere to dosing and visit schedules as
             well as meet all study requirements

          -  Patient has histologically or cytologically confirmed non-small cell lung cancer not
             amenable to curative intent therapy or stage IV NSCLC

          -  Specific mutations:

               -  Documented EGFR exon 20 insertion mutation

               -  Documented HER2 exon 20 insertion mutation

          -  Patient has had at least one prior systemic therapy for metastatic disease

          -  Patient has adequate organ function at Baseline

          -  Patient is at least 18 years of age

        Exclusion Criteria:

          -  Patient has had previous treatment with poziotinib or any other EGFR or HER2 exon 20
             insertion mutation tyrosine kinase inhibitor prior to study participation

          -  Patient is concurrently receiving chemotherapy, biologics, immunotherapy for cancer
             treatment; systemic anti-cancer treatment or investigational treatment

          -  Patient has a history of other malignancies within the last 5 years, except for
             non-melanoma skin cancer or carcinoma in situ of the cervix

          -  Patient is pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zang Yang, MD</last_name>
    <phone>(949)743-9291</phone>
    <email>spi-poz-202@sppirx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjay Mourya</last_name>
    <phone>(949)743-9322</phone>
    <email>spi-poz-202@sppirx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Regional Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Sangal, MD</last_name>
      <phone>623-207-3000</phone>
      <email>westerntrials@ctca-hope.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Fok</last_name>
      <phone>626-218-4438</phone>
      <email>kreckamp@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Nunez, MS</last_name>
      <phone>562-590-0345</phone>
      <phone_ext>258</phone_ext>
      <email>karenn@pacshoresoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Tse, RN</last_name>
      <phone>323-865‐0514</phone>
      <email>Tse_G@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayra Gonzalez</last_name>
      <phone>415-353-7912</phone>
      <email>mayra.gonzalez@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Santa Monica Hemotology/Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tawny Williams</last_name>
      <phone>310-829-5471</phone>
      <email>TJWilliams@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University, Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kira Pavlik, MPH</last_name>
      <phone>203-737-2587</phone>
      <email>Kira.Pavlik@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Crawford</last_name>
      <phone>202-687-0893</phone>
      <email>crawfojg@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Coakley</last_name>
      <phone>407-303-3235</phone>
      <email>Susan.Coakley@flhosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germaine Gonzalez Vazquez</last_name>
      <phone>813-745-6636</phone>
      <email>Germaine.GonzalezVazquez@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bond &amp; Steele Clinic</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Denmark</last_name>
      <phone>863-293-1191</phone>
      <email>ndenmark@bondclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Schied</last_name>
      <phone>208-367-3481</phone>
      <email>Tina.schied@saintalphonsus.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Highland Clinic, APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassia Roulia</last_name>
      <phone>318-716-4131</phone>
      <email>vroulia@brf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Ventimigilia</last_name>
      <phone>313-576-9813</phone>
      <email>ventimij@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Molina, MD</last_name>
      <phone>507-284-5352</phone>
      <email>Molina.Julian@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-288-2495</phone>
      <email>tmcbeth@forrestgeneral.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Parrish, LPN</last_name>
      <phone>631-675-5289</phone>
      <email>fparrish@nycancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hull, RN</last_name>
      <phone>212-731-5111</phone>
      <email>jennifer.hull@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Suyeon Velo, RN</last_name>
      <phone>212-731-5405</phone>
      <email>Suyeon.Velo@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Leena Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Parker</last_name>
      <phone>919-681-3510</phone>
      <email>Ellen.s.parker@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Essien</last_name>
      <phone>614-366-6387</phone>
      <email>Ellen.Essien@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dahlia Mack</last_name>
      <phone>713-745-8532</phone>
      <email>dahmack@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Daveta Jenkins</last_name>
      <phone>713-745-6768</phone>
      <email>dmjones4@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Masterson</last_name>
      <phone>206-606-7445</phone>
      <email>smasters@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Cancer Institue</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ma, MD</last_name>
      <phone>304-293-4229</phone>
      <email>pcma@hsc.wvu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>HER2</keyword>
  <keyword>Exon 20 insertion mutation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

